COVID-19 and flu activity is increasing in most parts of the country and RSV activity remains very high, especially in young children. Respiratory illness activity in Florida is very high ...
Winter is usually accompanied by an uptick in respiratory illnesses, such as Covid-19 and RSV, and 2025 is no exception. For RSV in particular, nearly two dozen states are currently reporting high ...
It's flu season. And COVID season. And RSV season. The Centers for Disease Control and Prevention (CDC) reported that as of last week, "the amount of acute respiratory illness causing people to ...
Cases of RSV across the country are considered "very high," as rates of other acute respiratory illnesses are also high, the CDC reported Monday. Here's what to know about RSV. Iowa currently is ...
The FDA will require GSK and Pfizer to include on the label of their respiratory syncytial virus (RSV) vaccines a warning about the risk of developing Guillain-Barré syndrome (GBS), a rare ...
Many health experts have compared HMPV to Respiratory Syncytial Virus (RSV), which can affect all age groups but is more common in children. According to the World Health Organization (WHO), HMPV ...
Both Lehigh Valley and St. Luke’s University health networks report increased hospitalizations related to influenza and respiratory syncytial virus, two of the most common respiratory infections ...
The National Notifiable Diseases Surveillance System recorded 175,786 cases of respiratory syncytial virus in 2024. It is the highest number of cases recorded since the virus became notifiable.
Two significant causes are human metapneumovirus (HMPV) and respiratory syncytial virus (RSV). Although they are members of the same Pneumovirus family, these viruses have distinct epidemiological ...
According to the FDA, the benefits of vaccination with Abrysvo and Arexvy continue to outweigh the potential risks. The prescribing information for Abrysvo ® (respiratory syncytial virus [RSV ...
FDA adds warning label to RSV vaccines Abrysvo and Arexvy about the risk for Guillain-Barré syndrome
Arexvy has been approved for the prevention of lower respiratory tract disease caused by RSV in all individuals 60 years of age and older and for those aged 50 to 59 years at increased risk.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback